



ten23 health celebrates the FDA approval of scPharmaceuticals` large volume subcutaneous product FUROSCIX® (furosemide injection)

Visp, November 14, 2022: ten23 health®, a global contract development and manufacturing organization (CDMO), celebrates the success of scPharmaceuticals, a pharmaceutical company headquartered in Burlington, MA USA, focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies. ten23 was pivotal in supporting scPharmaceuticals' for the U.S. Food and Drug Administration's (FDA) approval of FUROSCIX® (furosemide injection) with the implementation and fill/finish of the large (10 mL) volume polymer cartridges of the delivery device. FUROSCIX® is the first and only FDA-approved subcutaneous loop diuretic that can be self-administered at-home.

"We are very happy to have supported scPharmaceuticals in the development of FUROSCIX which they expect to commercially launch in Q1 2023. With our unique capability and expertise in filling complex sterile drug products such as the 10 mL polymer pre-filled cartridge used in the On-Body Infusor for FUROSCIX, we provide comprehensive solutions to our partners," says Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health.

FUROSCIX enables subcutaneous administration at home by the patient or a caregiver with the use of the On-Body Infusor for FUROSCIX. The pre-filled cartridge is inserted into the pre-programmed single-use On-Body Infusor for FUROSCIX, attached to the abdomen and then activated with the press of a button to deliver the dose over five hours. The FUROSCIX infusor will deliver only an 80-mg dose.

ten23 health's expertise and focus is on patients, improved formulations and delivery of parenteral drugs. Our scientific, regulatory and applied industrial knowhow in combination with our unique technical development and sterile manufacturing capabilities, enable customers to enter clinical testing and commercialization with high-precision and low-headspace pre-filled syringes or cartridge-based systems alike, using most recent delivery technologies, in close collaboration with device manufacturers and primary packaging suppliers.

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company's lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

About ten23 health

ten23 health®, located in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. Swissfillon, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly owned subsidiary of ten23 health. ten23 health combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner. For more information, visit: www.ten23.health

About the company's name

The numeric value for the number of molecules in a sample of one mol is called the Avogadro constant and equals $6.022 \cdot 10^{23}$. The world is built from small units, and not a homogeneous mass.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health; +41 27 948 90 90

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021